

## Appendix 1. Change in Hemoglobin Levels by Iron Preparation Use

Hemoglobin, g/dL		Relugolix (n=138)		Leuprorelin Acetate (n=142)	
Visit	<i>Change from baseline,</i>		<i>Change from baseline,</i>		
	N	<i>median (interquartile range)</i>	N	<i>median (interquartile range)</i>	
<i>Patients using oral iron preparations at baseline</i>					
Week 12	38	1.9 (1.10 to 2.90) g/dL	38	1.8 (1.10 to 2.80) g/dL	
Week 24	34	1.9 (1.20 to 2.90) g/dL	35	2.1 (1.40 to 2.80) g/dL	
<i>Patients not using oral iron preparations at baseline</i>					
Week 12	91	1.0 (0.50 to 1.70) g/dL	102	1.1 (0.60 to 1.70) g/dL	
Week 24	88	1.3 (0.55 to 2.30) g/dL	96	1.3 (0.65 to 2.30) g/dL	

Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. *Obstet Gynecol* 2019; 133.

The authors provided this information as a supplement to their article.

©2019 American College of Obstetricians and Gynecologists.

## Appendix 2. Change in Bone Metabolism Markers

Endpoint		Relugolix (n=138)		Leuprorelin Acetate (n=142)	
Visit	N	% change from baseline, median (interquartile range)		% change from baseline, median (interquartile range)	
<i>N-telopeptide</i>					
Week 12	138	30.7 (12.90 to 48.80)		142	28.9 (11.80 to 51.50)
Week 24	126	42.5 (21.10 to 68.20)		132	41.5 (22.55 to 68.65)
<i>Bone-specific alkaline phosphatase</i>					
Week 12	138	24.7 (7.70 to 43.20)		142	25.6 (10.30 to 37.50)
Week 24	126	41.4 (20.60 to 71.00)		132	46.5 (23.80 to 65.80)

Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuporelin injections for uterine leiomyomas: a randomized controlled trial. *Obstet Gynecol* 2019; 133.

The authors provided this information as a supplement to their article.

©2019 American College of Obstetricians and Gynecologists.

### Appendix 3. Change in Hormone Levels

Endpoint	Relugolix (n=138)		Leuporelin Acetate (n=142)	
Visit		<i>Change from baseline,</i>		<i>Change from baseline, median</i>
	<b>N</b>	<b>median (interquartile range)</b>	<b>N</b>	<b>(interquartile range)</b>
<i>Luteinizing hormone, mIU/mL</i>				
Week 12	129	-2.5 (-3.98 to -0.93) mIU/mL	140	-3.0 (-4.24 to -2.14) mIU/mL
Week 24	122	-2.1 (-3.77 to -0.67) mIU/mL	131	-3.10 (-4.28 to -2.15) mIU/mL
<i>Follicle stimulating hormone, mIU/mL</i>				
Week 12	129	-4.0 (-7.32 to -1.55) mIU/mL	140	-2.8 (-5.08 to -1.12) mIU/mL
Week 24	122	-3.8 (-7.14 to -1.31) mIU/mL	131	-2.1 (-4.72 to -0.94) mIU/mL
<i>Estradiol, pg/mL</i>				
Week 12	129	-27.0 (-44.0 to -14.0) pg/mL	140	-30.0 (-48.5 to -14.0) pg/mL
Week 24	122	-31.0 (-49.0 to -16.0) pg/mL	131	-29.0 (-54.0 to -15.0) pg/mL
<i>Progesterone, ng/mL</i>				
Week 12	129	-0.1 (-0.20 to 0.00) ng/mL	140	-0.1 (-0.20 to 0.00) ng/mL

Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuporelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2019; 133.

The authors provided this information as a supplement to their article.

©2019 American College of Obstetricians and Gynecologists.

Week 24	122	0.0 (-0.10 to 0.00) ng/mL	131	-0.1 (-0.10 to 0.00) ng/mL
---------	-----	---------------------------	-----	----------------------------

---

Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. *Obstet Gynecol* 2019; 133.

The authors provided this information as a supplement to their article.

©2019 American College of Obstetricians and Gynecologists.